1 Min Read
NEW YORK, Dec 17 (Reuters) - Athersys Inc : * Up 13.5 percent to $2.31 in premarket; says stem cell therapy gets orphan drug designation in Europe for prevention of graft-versus-host disease
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.